Examining Clinical and Cost Implications of HER+ Breast Cancer Care in a New Era of Value-Based Care: Biosimilars, Clinical Pathways, and Precision Medicine

Examining Clinical and Cost Implications of HER+ Breast Cancer Care in a New Era of Value-Based Care: Biosimilars, Clinical Pathways, and Precision Medicine

Live Webinar
Date Time
Monday, June 26, 2017 12:00pm to 1:00pm ET Register
Tuesday, June 27, 2017 1:00pm to 2:00pm ET Register
Wednesday, June 28, 2017 2:00pm to 3:00pm ET Register
Thursday, June 29, 2017 1:00pm to 2:00pm ET Register
Faculty

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Director, Comprehensive Breast Cancer Center
Associate Director, Clinical Investigation
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Edward Li, PharmD, MPH, BCOP
Associate Professor
University of New England College of Pharmacy
Scarborough, Maine

Intended Learners

This activity is designed for pharmacy directors, medical directors, and other decision makers working in managed care organizations.

Learning Objectives

After completing this activity, participants should be able to:

  • Evaluate the latest clinical evidence surrounding HER-directed therapies in the individualized management of breast cancer in the United States
  • Explore the impact of clinical pathways on breast cancer management with respect to practice variation, guideline adherence, efficiency and cost of care, and patient outcomes
  • Apply recent clinical/cost data, value-based guidance, survival outcomes to plan benefits design and formulary discussions
  • Highlight the differences among reference biologics, biosimilars, and generic drugs in terms of their manufacturing processes, clinical considerations, regulatory parameters and labeling, interchangeability, extrapolation of indications, safety/efficacy, cost-benefit, and patient impact
  • Identify the clinical and cost considerations that impact the widespread acceptance of biosimilars among clinicians, patients, payers in the setting of HER+ breast cancer
Activity Overview

In order to be eligible for documentation of credit, participants must complete the pre-test, attend the full webinar, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at www.naccme.com, participants may immediately print their documentation of credit.

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.

ACPE Credit Policy

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. The reporting function into CPE Monitor will only be available for 60 days after your completion of the activity.  Under ACPE Policy, NACCME will not be able to report your credit to CPE Monitor after this 60 day period.

Hardware/Software Requirements

All educational activities are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. Windows Media Player or compatible alternative, sound card, and speakers are required for streamed audio. The latest version of the Adobe Flash Player is suggested for video programs (please download here). A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation

    In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Save

CME

NACCME designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This activity is approved for 1.0 contact hour (.1 CEUs) of continuing pharmacy education (UAN 0276-0000-17-096-L01-P).

This educational activity is a knowledge-based activity.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Independent Clinical Reviewer: Neil M. Iyengar, MD, Attending Medical Oncologist, Memorial Sloan Kettering Cancer Center, Associate Physician, Rockefeller University, Assistant Professor of Medicine, Weill Cornell Medical College, New York, New York

Planning Committee

The planning committee comprises Adam M. Brufsky, MD, PhD, Neil M. Iyengar, MD, Edward Li, PharmD, MPH, BCOP; and Donna Brophy, Kristin Ciszeski, Mary Johnson, Michael Kearney, Susan Kuhn, Michelle Montgomery, Randy Robbin, John Savage, and Sydney Turner, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Dr. Brufsky: ConsultantPuma, Roche

Dr. Li: Speakers' BureauPfizer/Hospira; Advisory BoardEli Lilly, Pfizer; HonorariumApoBiologix

Dr. Iyengar has disclosed no relevant financial relationships with any commercial interest.

Ms. Brophy, Ms. Ciszeski, Ms. Johnson, Mr. Kearney, Ms. Montgomery, Mr. Robbin, Mr. Savage and Ms. Turner have disclosed no relevant financial relationships with any commercial interests.

Ms. Kuhn: Stock Shareholder (spouse)—Osiris Pharmaceuticals

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed that the off label/unapproved use of a hypothetical biosimilar trastuzumab in combination with therapies outside of the label will be discussed in the presentations.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Grant Support

This activity is supported by an educational grant from Genentech.